In brief
The latest modelling study published in *Nature Medicine* projects a 20.2 % increase in cervical cancer cases and a 39.3 % rise in deaths worldwide by 2050, with sub‑Saharan Africa expected to see the most dramatic surge. The analysis, based on data from 204 countries, stresses that current trends will not meet WHO elimination targets. The findings highlight the uneven access to HPV vaccines, screening and treatment as a key driver of the projected escalation.
Australian and international researchers have modeled the trajectory of cervical cancer worldwide, projecting that annual cases will rise 20.2 % and deaths will climb 39.3 % by 2050, according to a study published in *Nature Medicine* and summarized by Xinhua on Nov. 3.
Xinhua reports that in 2023 there were 887,000 new cervical cancer cases globally and 369,000 deaths, and that by 2050 the expected numbers would reach 1.08 million cases and 522,000 deaths. The study highlights that sub‑Saharan Africa is poised for the greatest increase, with cases projected to surge 88.7 % and deaths 95.4 %, reaching an estimated 206,000 deaths in 2050.
Medicalxpress, in a brief news note, echoes these figures, noting the same projected 88.7 % rise in cases and 95.4 % rise in deaths for sub‑Saharan Africa. The same source emphasizes that the 206,000 deaths estimate matches the *Nature Medicine* model.
Epocrates’ online article also cites the *Nature Medicine* modeling, reporting an annual rise of 20 % in cases to about 1.08 million by 2050 and a 39 % increase in deaths to roughly 522,000.
The Xinhua piece further clarifies that none of the seven global regions studied are on track to reach the World Health Organization’s elimination threshold of fewer than four cervical cancer cases per 100,000 women by 2050 if current trends persist.
In the same summary, Xinhua notes that in 2023 the age‑standardized incidence rate of cervical cancer was more than four times higher in low‑income countries than in high‑income countries, while the mortality rate was over seven times higher, underscoring a stark disparity in disease burden tied to socioeconomic status.
Authors of the *Nature Medicine* study called for expanded access to human papillomavirus (HPV) vaccination, widespread screening and timely treatment, arguing that such measures are key to reversing the projected trend.
While the modelling offers a stark warning, it also points to clear policy levers—improving vaccine coverage, scaling up screening programs and ensuring equitable treatment access—to potentially curb the looming rise in cervical cancer cases and deaths worldwide.
